Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Down 88.6% in December

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 238 shares, a drop of 88.6% from the December 15th total of 2,079 shares. Based on an average trading volume of 18,904 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 18,904 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group initiated coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Alterity Therapeutics Stock Performance

ATHE opened at $3.40 on Wednesday. Alterity Therapeutics has a 12 month low of $2.52 and a 12 month high of $7.00. The company has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $4.25.

Institutional Investors Weigh In On Alterity Therapeutics

Hedge funds have recently modified their holdings of the business. Greenleaf Trust acquired a new position in shares of Alterity Therapeutics in the 2nd quarter valued at approximately $70,000. Twin Lakes Capital Management LLC lifted its stake in Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares in the last quarter. HB Wealth Management LLC acquired a new position in shares of Alterity Therapeutics in the third quarter valued at approximately $220,000. Finally, Citadel Advisors LLC bought a new stake in shares of Alterity Therapeutics during the third quarter worth $83,000. Institutional investors and hedge funds own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.